Comparative Pharmacology
Head-to-head clinical analysis: MAXZIDE 25 versus ORETICYL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXZIDE 25 versus ORETICYL FORTE.
MAXZIDE-25 vs ORETICYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Maxzide-25 is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, and triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the collecting duct by blocking epithelial sodium channels.
Thiazide diuretic; inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
1 tablet (triamterene 37.5 mg/hydrochlorothiazide 25 mg) orally once daily.
Hydrochlorothiazide (HCTZ) 50 mg and deserpidine 0.5 mg orally once daily.
None Documented
None Documented
Triamterene: 2-4 hours (terminal half-life due to active metabolite hydroxylated triamterene, clinical effect persists 12-16 hours). Hydrochlorothiazide: 5.6-14.8 hours (mean 8.5 hours).
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Deserpidine: 4-12 hours.
Renal: triamterene 80-85% (as metabolites, 5-10% unchanged), hydrochlorothiazide ≥95% unchanged via tubular secretion; biliary/fecal: minimal (<5% each).
Renal excretion: ~70% as hydrochlorothiazide unchanged; ~30% as deserpidine metabolites via bile/feces.
Category C
Category C
Diuretic Combination
Diuretic Combination